Kite Pharma (KITE) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts KITE Hot Sheet
Join SI Premium – FREE
Kite Pharma (NASDAQ: KITE) reported Q3 EPS of ($0.38), $0.26 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $4.09 million.
Kite's guidance remains unchanged. Kite expects to burn between $100 million and $125 million in cash for the full year 2015, which includes both operating expenses and capital expenditures. This guidance does not include cash inflows or outflows for business development activities.
For earnings history and earnings-related data on Kite Pharma (KITE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Penguin Solutions (PENG) Tops Q4 EPS by 23c, Offers Guidance
- HIMS jumps 7% on peptide tailwind but Citi sees 17% downside from here
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
